Market Cap
US$1.0b
Last Updated
2021/01/19 00:35 UTC
Data Sources
Company Financials +
Executive Summary
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. More Details
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with mediocre balance sheet.
Share Price & News
How has Athenex's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ATNX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ATNX's weekly volatility (8%) has been stable over the past year.
Market Performance
7 Day Return
-0.2%
ATNX
3.2%
US Biotechs
-0.4%
US Market
1 Year Return
-27.2%
ATNX
36.8%
US Biotechs
19.5%
US Market
Return vs Industry: ATNX underperformed the US Biotechs industry which returned 36.8% over the past year.
Return vs Market: ATNX underperformed the US Market which returned 19.6% over the past year.
Shareholder returns
| ATNX | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.2% | 3.2% | -0.4% |
| 30 Day | -3.6% | 4.8% | 2.3% |
| 90 Day | -7.0% | 22.4% | 12.7% |
| 1 Year | -27.2%-27.2% | 39.0%36.8% | 22.3%19.5% |
| 3 Year | -32.0%-32.0% | 27.5%20.8% | 44.4%34.8% |
| 5 Year | n/a | 46.3%35.2% | 128.7%103.3% |
Long-Term Price Volatility Vs. Market
How volatile is Athenex's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Reflecting on Athenex's (NASDAQ:ATNX) Share Price Returns Over The Last Year1 month ago | Simply Wall St
Athenex (NASDAQ:ATNX) Is Using Debt Safely1 month ago | Simply Wall St
Is Athenex, Inc. (NASDAQ:ATNX) Popular Amongst Insiders?Valuation
Is Athenex undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ATNX ($11.11) is trading below our estimate of fair value ($94.09)
Significantly Below Fair Value: ATNX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ATNX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ATNX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ATNX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ATNX is overvalued based on its PB Ratio (4.6x) compared to the US Biotechs industry average (4.2x).
Next Steps
Future Growth
How is Athenex forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
63.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ATNX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: ATNX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ATNX's is expected to become profitable in the next 3 years.
Revenue vs Market: ATNX's revenue (35.2% per year) is forecast to grow faster than the US market (10.3% per year).
High Growth Revenue: ATNX's revenue (35.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ATNX's Return on Equity is forecast to be low in 3 years time (3.7%).
Next Steps
Past Performance
How has Athenex performed over the past 5 years?
-8.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ATNX is currently unprofitable.
Growing Profit Margin: ATNX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ATNX is unprofitable, and losses have increased over the past 5 years at a rate of 8.6% per year.
Accelerating Growth: Unable to compare ATNX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: ATNX has a negative Return on Equity (-56.75%), as it is currently unprofitable.
Next Steps
Financial Health
How is Athenex's financial position?
Financial Position Analysis
Short Term Liabilities: ATNX's short term assets ($324.2M) exceed its short term liabilities ($66.6M).
Long Term Liabilities: ATNX's short term assets ($324.2M) exceed its long term liabilities ($130.9M).
Debt to Equity History and Analysis
Debt Level: ATNX's debt to equity ratio (57.9%) is considered high.
Reducing Debt: ATNX's debt to equity ratio has increased from 3.4% to 57.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ATNX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ATNX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Athenex current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ATNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ATNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ATNX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ATNX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ATNX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.8yrs
Average management tenure
CEO
Johnson Lau (60 yo)
10yrs
Tenure
US$4,483,836
Compensation
Dr. Yiu-Nam Lau, also known as Johnson, MBBS, MD, FRCP, Ph.D., has been the Chief Executive Officer of Athenex, Inc. since 2011. Dr. Lau is the Vice Chairman and CEO of Axis Therapeutics. Dr. Lau serves as...
CEO Compensation Analysis
Compensation vs Market: Johnson's total compensation ($USD4.48M) is above average for companies of similar size in the US market ($USD2.41M).
Compensation vs Earnings: Johnson's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 10yrs | US$4.48m | 3.57% $ 37.0m | |
| Chief Financial Officer | 2.42yrs | US$942.99k | 0.0064% $ 66.7k | |
| COO & President of Athenex Pharmaceutical Division | 3.92yrs | US$1.39m | 0.25% $ 2.6m | |
| Chief Medical Officer | 7yrs | US$1.47m | 0.15% $ 1.6m | |
| Chief Business & Strategy Officer of Proprietary Products | 3.83yrs | US$860.55k | 0.0057% $ 59.0k | |
| Co-Founder & President Emeritus | 10yrs | no data | no data | |
| General Counsel | 2.08yrs | no data | no data | |
| Senior Director of Investor Relations | no data | no data | no data | |
| Director of Corporate Development & Investor Relations | 1yr | no data | no data | |
| Senior Director of Corporate Development | 2yrs | no data | no data | |
| Vice President of Human Resources | no data | no data | no data | |
| Deputy Chief Medical Officer of Orascovery & Src Kinase Platforms | no data | no data | no data |
3.8yrs
Average Tenure
60yo
Average Age
Experienced Management: ATNX's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 10yrs | US$4.48m | 3.57% $ 37.0m | |
| Independent Director | 1.75yrs | US$114.74k | 0.0019% $ 20.0k | |
| Independent Director | 13.75yrs | US$149.96k | 0.43% $ 4.5m | |
| Director | 0.42yr | no data | no data | |
| Independent Director | 2.5yrs | US$184.04k | 0.011% $ 111.1k | |
| Independent Director | 1.75yrs | US$117.74k | 0.0050% $ 51.4k | |
| Director | 5.58yrs | US$105.81k | 2.14% $ 22.2m | |
| Lead Independent Director | 4.08yrs | US$151.96k | 0% $ 0 | |
| Independent Director | 1.75yrs | US$156.24k | 0.021% $ 222.2k |
2.5yrs
Average Tenure
63yo
Average Age
Experienced Board: ATNX's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ATNX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.6%.
Top Shareholders
Company Information
Athenex, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Athenex, Inc.
- Ticker: ATNX
- Exchange: NasdaqGS
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.037b
- Shares outstanding: 93.34m
- Website: https://www.athenex.com
Number of Employees
Location
- Athenex, Inc.
- Conventus Building
- Suite 600
- Buffalo
- New York
- 14203
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ATNX | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Jun 2017 |
| 2MT | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 2017 |
Biography
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. I...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/19 00:35 |
| End of Day Share Price | 2021/01/15 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.